Plasmid DNA purification and formulation for vaccine applications

Gareth M. Forde; James Friend; Michael Danquah; Ying Han; Tom Williamson; Anthony D. Coomes; Fiona K. Giliam; Miranda J. Horsfall

Plasmid DNA purification and formulation for vaccine applications

Gareth M. Forde
, James Friend
, Michael Danquah
, Ying Han
, Tom Williamson
, Anthony D. Coomes
, Fiona K. Giliam
, Miranda J. Horsfall

Research output: Contribution to conference › Paper › peer-review

Abstract

Plasmid DMA offers the promise of a new generation of pharmaceuticals that will address the often overlooked issue of vaccine production by offering a simple and reproducible method for producing a vaccine. Through reverse engineering, production could be reduced from up to 9 months to as little as 1 month. Simplified development and faster turn-around times means that DMA offers a solution to the vaccine crisis and will help to contain future viral outbreaks by enabling the production of a vaccine against new viral strains in the shortest possible time. Work currently being completed in the area of plasmid DMA production, purification and encapsulation will be presented.

Original language	English
Pages	12151-12163
Number of pages	13
State	Published - 2005
Event	05AIChE: 2005 AIChE Annual Meeting and Fall Showcase - Cincinnati, OH, United States Duration: Oct 30 2005 → Nov 4 2005

Conference

Conference	05AIChE: 2005 AIChE Annual Meeting and Fall Showcase
Country/Territory	United States
City	Cincinnati, OH
Period	10/30/05 → 11/4/05

Cite this

@conference{6cfa408386494181a8ef84c59b2b7880,

title = "Plasmid DNA purification and formulation for vaccine applications",

abstract = "Plasmid DMA offers the promise of a new generation of pharmaceuticals that will address the often overlooked issue of vaccine production by offering a simple and reproducible method for producing a vaccine. Through reverse engineering, production could be reduced from up to 9 months to as little as 1 month. Simplified development and faster turn-around times means that DMA offers a solution to the vaccine crisis and will help to contain future viral outbreaks by enabling the production of a vaccine against new viral strains in the shortest possible time. Work currently being completed in the area of plasmid DMA production, purification and encapsulation will be presented.",

author = "Forde, \{Gareth M.\} and James Friend and Michael Danquah and Ying Han and Tom Williamson and Coomes, \{Anthony D.\} and Giliam, \{Fiona K.\} and Horsfall, \{Miranda J.\}",

year = "2005",

language = "English",

pages = "12151--12163",

note = "05AIChE: 2005 AIChE Annual Meeting and Fall Showcase ; Conference date: 30-10-2005 Through 04-11-2005",

}

TY - CONF

T1 - Plasmid DNA purification and formulation for vaccine applications

AU - Forde, Gareth M.

AU - Friend, James

AU - Danquah, Michael

AU - Han, Ying

AU - Williamson, Tom

AU - Coomes, Anthony D.

AU - Giliam, Fiona K.

AU - Horsfall, Miranda J.

PY - 2005

Y1 - 2005

N2 - Plasmid DMA offers the promise of a new generation of pharmaceuticals that will address the often overlooked issue of vaccine production by offering a simple and reproducible method for producing a vaccine. Through reverse engineering, production could be reduced from up to 9 months to as little as 1 month. Simplified development and faster turn-around times means that DMA offers a solution to the vaccine crisis and will help to contain future viral outbreaks by enabling the production of a vaccine against new viral strains in the shortest possible time. Work currently being completed in the area of plasmid DMA production, purification and encapsulation will be presented.

AB - Plasmid DMA offers the promise of a new generation of pharmaceuticals that will address the often overlooked issue of vaccine production by offering a simple and reproducible method for producing a vaccine. Through reverse engineering, production could be reduced from up to 9 months to as little as 1 month. Simplified development and faster turn-around times means that DMA offers a solution to the vaccine crisis and will help to contain future viral outbreaks by enabling the production of a vaccine against new viral strains in the shortest possible time. Work currently being completed in the area of plasmid DMA production, purification and encapsulation will be presented.

UR - https://www.scopus.com/pages/publications/33645639880

M3 - Paper

AN - SCOPUS:33645639880

SP - 12151

EP - 12163

T2 - 05AIChE: 2005 AIChE Annual Meeting and Fall Showcase

Y2 - 30 October 2005 through 4 November 2005

ER -

Plasmid DNA purification and formulation for vaccine applications

Abstract

Conference

Other files and links

Fingerprint

Cite this